hyperprolactinemia

Not Applicable

• Conditions: Hyperprolactinaemia.; Hyperprolactinaemia; E 22.1

• Registration Number: IRCT2013122215891N1
• Lead Sponsor: Dr. Minaei; Vice chancellor for research Traditional Medicine Faculty of Tehran University of Medica

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 158

Inclusion Criteria

Patient satisfaction; Female; Outpatients older than 18 years; Patient with asymptomatic or mild symptoms idiopathic hyperprolactinemia (menstrual disorders that are just starting with or without galactorrhea or without bothering galactorrhea alone); Serum prolactin level above 25 µgr/L
Exclusion criteria: Patients older than 45 years; Patient with liver failure; Patient with kidney failure; Patient with hypothyroidism; Taking medication such as haloperidol, phenothiazine, butyrophenone, monoamine oxidase inhibitor, fluoxetine, sulpiride, metoclopramide, domperidone, tricyclic antidepressants, opioid, estrogen, verapamil, reserpine, methyldopa, benzodiazepine, cimetidine, medroxolol drugs and any medication that is effective in prolactin secretion in the last three months; The use of warfarin; The use of sedating; Prolactinoma( micro or macro adenoma); Adrenal, pituitary and hypothalamus disease; Pregnant women; Women who plan to become pregnant; Breast feeding; Autoimmune disease such as lupus; Long- term menstural disorders; Bothering galactorrhea; Underlying disease such as diabetes, hypertension and cancer; History of hyperprolactinemia treatment in the last 6 months; The use of propranolol and vasoconstrictor drugs; Raynaud’s disease; History sensitivity to ergot derivatives; History of stomach ulcers and gastrointestinal bleeding; Asthma; History of hay fever and allergic reaction to member of the compositae family such as yarrow, feverfew, artemisia, tansy

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum prolactin level. Timepoint: Before and after the intervention. Method of measurement: Laboratory measurement.

Secondary Outcome Measures

Name	Time	Method
Side effects. Timepoint: During the treatment. Method of measurement: questionnaire and Physical exam.